Dr. Matthew P Deek, MD
Claim this profileRutgers Cancer Institute of New Jersey
Affiliated Hospitals
Rutgers Cancer Institute Of New Jersey
RWJBarnabas Health - Robert Wood Johnson University Hospital
Clinical Trials Matthew P Deek, MD is currently running
High-Dose Radiation
for Bone Metastases Pain
The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases
Recruiting
1 award
Phase 2
11 criteria
Peposertib + Radiation Therapy
for Pancreatic Cancer
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and/or more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer.
Recruiting
0 awards
Phase 1 & 2
3 criteria
More about Matthew P Deek, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Matthew P Deek, MD has experience with
- EXTERNAL BEAM RADIATION
- AN0025
- Capecitabine
- Fluorouracil
- Intensity-Modulated Radiation Therapy
- Mitomycin
Breakdown of trials Matthew P Deek, MD has run
Bone Cancer
Lung Cancer
Anal Canal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew P Deek, MD specialize in?
Matthew P Deek, MD focuses on Cancer and Bone Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Matthew P Deek, MD currently recruiting for clinical trials?
Yes, Matthew P Deek, MD is currently recruiting for 3 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Matthew P Deek, MD has studied deeply?
Yes, Matthew P Deek, MD has studied treatments such as EXTERNAL BEAM RADIATION, AN0025, Capecitabine.
What is the best way to schedule an appointment with Matthew P Deek, MD?
Apply for one of the trials that Matthew P Deek, MD is conducting.
What is the office address of Matthew P Deek, MD?
The office of Matthew P Deek, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.